HRS-1167 tablets + Prednisone Acetate tablets + ABIRATERONE ACETATE for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 14 Nov 2024: Trial registered, NCT06689163
  2. 11 Dec 2024: Trial started, NCT06689163

The trials

NCT06689163: A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone

State
Under way
Phase
Phase 1 and Phase 2
People
66 planned
Started
11 Dec 2024
Primary completion
30 Nov 2025
Arms
HRS-1167 combined with abiraterone acetate tablets (II) and prednisone
Results
None posted
  1. 14 Nov 2024: Trial registered
  2. 11 Dec 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.